Rubric condition met: C: one RCT of magnesium alone (n = 100, supplier-funded) plus one multi-ingredient RCT; an NIH-funded meta-analysis judged RCT evidence insufficient
A 6-week Threotech-funded trial of magnesium L-threonate in 100 adults with dissatisfied sleep found a greater improvement on the NIH Total Cognition Composite (p = 0.043), with larger effects on working and episodic memory, but no difference on Raven's test. A second trial tested a multi-ingredient formula and was funded by the ingredient maker. A 2024 NIH-funded meta-analysis concluded RCT evidence was insufficient. With one funder, one product and an NIH-funded synthesis finding insufficient evidence, C is proposed.
How sure are we?
Evidence maturity: Early signal One magnesium-alone RCT (n = 100, supplier-funded, magnesium L-threonate) and one multi-ingredient RCT.
Tested as: Magnesium L-threonate (Magtein)
Who paid for the studies
All industry-funded
Risk of bias
Some concerns. The 2026 review that rates certainty low to very low is led by an author of the Threotech-funded trial and co-author of the bisglycinate trial. A 2026 correction to the Magtein trial is logged; its content was not read.
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Matched
Material tested
Magtein (magnesium L-threonate)
Doses used in studies
2 g a day of magnesium L-threonate
Rules applied
B2: one funder or group (logged, no further change): One funder and one product
Could rise: Would move to B with a non-supplier replication of the Magtein trial, preregistered, with cognition as primary.
Could fall: Would move to C none with an adequately sized null replication.
Science is provisional. This grade reflects the evidence we found as of . Next review: .
Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.
Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.Show the numbers
Study
Year
Design
Participants
Result
Zhang 2022
2022
RCT
109
result not recorded
Chen 2024
2024
meta-analysis
not recorded
result not recorded
Lopresti 2025
2025
RCT
100
result not recorded
A Magtein(®), Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults.
Zhang C, Hu Q, Li S. A Magtein(®), Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese Adults Nutrients, 2022. PMID 36558392
Result not recorded
Design
Randomized, double-blind, placebo-controlled trial, 30 days
Sample
n = 109
Population
Healthy Chinese adults aged 18-65
Funding
Wu-xi Magtein Bioscience (funding statement)
Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-Analysis.
Chen F, Wang J, Cheng Y. Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-Analysis Adv Nutr, 2024. PMID 39009081
Result not recorded
Design
Systematic review and meta-analysis of 3 RCTs and 12 cohort studies (PROSPERO CRD42023423663)
Population
Adults
Funding
National Institutes of Health; Tufts University (PubMed grants, Crossref funders)
The effects of magnesium L-threonate (Magtein(®)) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial.
Lopresti AL, Smith SJ. The effects of magnesium L-threonate (Magtein(®)) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial Front Nutr, 2025. PMID 41601871
Adults aged 18-45 with self-reported dissatisfied sleep
Funding
Threotech Inc. (COI statement)
Search and history
Search (): magnesium[ti] AND (cognition[tiab] OR cognitive[tiab] OR memory[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt])
Graded C (awaiting approval)
C to C (awaiting approval) (maturity: early signal): Maturity, bias summary and re-check date added
C to C (approved) (maturity: early signal): Editor sign-off November 16, 2026: grade matches the editor-approved final page
A, strong: what grade A means
At least one meta-analysis or three independent randomized trials in the relevant healthy population, pointing the same way, with low or some risk of bias, at doses legally available.